Status:
COMPLETED
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This prospective, multi-center, observational study will assess the safety and efficacy of Avastin (bevacizumab) in daily practice in patients with metastatic colorectal cancer who have received no pr...
Eligibility Criteria
Inclusion
- Metastatic colorectal cancer with no previous systemic treatment for advanced disease
- Receiving Avastin in combination with a first-line standard of care chemotherapy regimen
- Avastin initiated at the same time as first-line chemotherapy regimen
Exclusion
- Investigational, non-standard of care first-line chemotherapy regimen for treatment of metastatic colorectal cancer
- Contraindication to Avastin
Key Trial Info
Start Date :
July 6 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 10 2017
Estimated Enrollment :
719 Patients enrolled
Trial Details
Trial ID
NCT01506167
Start Date
July 6 2012
End Date
March 10 2017
Last Update
May 14 2018
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal United Hospital Bath; Diabetes and Lipid Research, Wolfson Centre
Bath, United Kingdom, BA1 3NG
2
Wexham Park Hospital; Oncology
Berkshire, United Kingdom, SL2 4HL
3
Queen Elizabeth Hospital
Birmingham, United Kingdom, B15 2TH
4
Birmingham Heartlands Hospital; Dept of Oncology
Birmingham, United Kingdom, B9 5SS